Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Menveo in Adults
NCT00474487Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2007
- Primary completion
- Aug 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (4 arms), sponsored by Novartis. Primary endpoint: Number of Subjects With at Least One Severe Systemic Reaction. Started May 2007; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00474487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474487.